Worth reading
83Important
Scored from 3 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-167
¥ millions (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationQ3 of the fiscal year ending December 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales4,589 Millions of yen+8.5%
Operating profit156 Millions of yen-51.7%
Ordinary income171 Millions of yen-47.2%
Net income169 Millions of yen-74.7%
Gross Profit Margin52.4%
Operating profit margin3.4%
Selling, general and administrative expenses2,247 Millions of yen
Results for the three months of the current quarter
Net Sales
1,953 Millions of yen
Pharmaceuticals business sales
1,801 Millions of yen
Infection control business revenue
149 Millions of yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Higher revenue from the pharmaceuticals business108 Millions of yen
- Impact of price-per-unit revisions for pharmaceuticals20 Millions of yen
- Lower revenue from the infection control business-64 Millions of yen
- Cost impact-145 Millions of yen
- Foreign exchange impact129 Millions of yen
- SG&A expenses-210 Millions of yen
- Other-6 Millions of yen
New initiatives
- Sales and marketing initiatives to expand sales in the major markets of China, Hong Kong and Taiwan
- Strengthen the brand campaign in Osaka for the 80th anniversary of the company's founding, including Osaka Metro train wrapping, station advertising and use of the official X account
- Resume supply of 200-count Seirogan packs
Key KPIsA metric the company considers important as a management benchmark.
- Domestic antidiarrheal market size (January–September 2026)3,241 Millions of yenYear on year against the same period last year+95.6%
- Taiko Pharmaceutical market share (July–September 2026)44.4 %
Segment results
Pharmaceuticals Business
Net Sales
4,324 Millions of yen+12.8%
Segment Profit or Loss
935 Millions of yen-14.6%
Infection Control Business
Net Sales
261 Millions of yen-33.1%
Segment Profit or Loss
-79 Millions of yen
Other Business
Net Sales
3 Millions of yen-16.2%
Segment Profit or Loss
-23 Millions of yen
Financial targets
Equity ratio
74.8 %
Market Size / Share
Domestic antidiarrheal market size
3,241 Millions of yen
Taiko Pharmaceutical share
44.4 %
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Q3 of the fiscal year ending December 2026 |
| Net Sales | 4,589 Millions of yen (YoY +8.5%) |
| Operating profit | 156 Millions of yen (YoY -51.7%) |
| Ordinary income | 171 Millions of yen (YoY -47.2%) |
| Net income | 169 Millions of yen (YoY -74.7%) |
| Gross Profit Margin | 52.4% |
| Operating profit margin | 3.4% |
| Selling, general and administrative expenses | 2,247 Millions of yen |
| Results for the three months of the current quarter | Net Sales 1,953 Millions of yen / Pharmaceuticals business sales 1,801 Millions of yen / Infection control business revenue 149 Millions of yen |
| Segment results | Pharmaceuticals Business Net Sales 4,324 Millions of yen (YoY +12.8%) / Segment Profit or Loss 935 Millions of yen (YoY -14.6%) / Infection Control Business Net Sales 261 Millions of yen (YoY -33.1%) / Segment Profit or Loss -79 Millions of yen / Other Business Net Sales 3 Millions of yen (YoY -16.2%) / Segment Profit or Loss -23 Millions of yen |
| Breakdown of Factors Affecting the Change | Factors Higher revenue from the pharmaceuticals business / Amount 108 Millions of yen, Factors Impact of price-per-unit revisions for pharmaceuticals / Amount 20 Millions of yen, Factors Lower revenue from the infection control business / Amount -64 Millions of yen, Factors Cost impact / Amount -145 Millions of yen, Factors Foreign exchange impact / Amount 129 Millions of yen, Factors SG&A expenses / Amount -210 Millions of yen, Factors Other / Amount -6 Millions of yen |
| Key KPIs | Indicator name Domestic antidiarrheal market size (January–September 2026) / Value 3,241 Millions of yen / Year on year against the same period last year 95.6 Millions of yen, Indicator name Taiko Pharmaceutical market share (July–September 2026) / Value 44.4 % / Year on year against the same period last year Not disclosed |
| Financial targets | Equity ratio 74.8 % |
| Market Size / Share | Domestic antidiarrheal market size 3,241 Millions of yen / Taiko Pharmaceutical share 44.4 % |
| New initiatives | Sales and marketing initiatives to expand sales in the major markets of China, Hong Kong and Taiwan, Strengthen the brand campaign in Osaka for the 80th anniversary of the company's founding, including Osaka Metro train wrapping, station advertising and use of the official X account, Resume supply of 200-count Seirogan packs |
Items this document does not state (15)
Full-year earnings forecastProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Higher revenue from the overseas pharmaceutical business, pharmaceutical price revisions and foreign exchange effects contributed to profit. Meanwhile, operating profit was pressured by higher raw material and supply prices, increased costs associated with strengthening the supply system, the impact of temporarily lower yields on cost of sales, and higher selling, general and administrative expenses associated with marketing initiatives. The decline in net profit was also affected by the reversal of gains on the sale of investment securities and gains on the reversal of the foreign currency translation adjustment account recorded in the same period of the previous year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.